Literature DB >> 30488274

Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years.

D Pienkowski1, C L Wood2, H H Malluche3.   

Abstract

Bone modulus from patients with osteoporosis treated with bisphosphonates for 1 to 20 years was analyzed. Modulus increases during the first 6 years of treatment and remains unchanged thereafter.
INTRODUCTION: Bisphosphonates are widely used for treating osteoporosis, but the relationship between treatment duration and bone quality is unclear. Since material properties partially determine bone quality, the present study quantified the relationship between human bone modulus and hardness with bisphosphonate treatment duration.
METHODS: Iliac crest bone samples from a consecutive case series of 86 osteoporotic Caucasian women continuously treated with oral bisphosphonates for 1.1-20 years were histologically evaluated to assess bone turnover and then tested using nanoindentation. Young's modulus and hardness were measured and related to bisphosphonate treatment duration by statistical modeling.
RESULTS: All bone samples had low bone turnover. Statistical models showed that with increasing bisphosphonate treatment duration, modulus and hardness increased, peaked, and plateaued. These models used quadratic terms to model modulus increases from 1 to 6 years of bisphosphonate treatment and linear terms to model modulus plateaus from 6 to 20 years of treatment. The treatment duration at which the quadratic-linear transition (join point) occurred also depended upon trabecular location. Hardness increased and peaked at 12.4 years of treatment; it remained constant for the next 7.6 years of treatment and was insensitive to trabecular location.
CONCLUSIONS: Bone modulus increases with bisphosphonate treatment durations up to 6 years, no additional modulus increases occurred after 6 years of treatment. Although hardness increased, peaked at 12.4 years and remained constant for the next 7.6 years of BP treatment, the clinical relevance of hardness remains unclear.

Entities:  

Keywords:  Bone biomechanics; Bone hardness; Bone modulus; Bone quality; Nanoindentation

Mesh:

Substances:

Year:  2018        PMID: 30488274     DOI: 10.1007/s00198-018-4760-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

1.  Age, gender, and bone lamellae elastic moduli.

Authors:  C E Hoffler; K E Moore; K Kozloff; P K Zysset; S A Goldstein
Journal:  J Orthop Res       Date:  2000-05       Impact factor: 3.494

Review 2.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

3.  Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.

Authors:  Ruth Zoehrer; Paul Roschger; Eleftherios P Paschalis; Jochen G Hofstaetter; Erich Durchschlag; Peter Fratzl; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-07       Impact factor: 6.741

4.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

5.  Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.

Authors:  Yohann Bala; Baptiste Depalle; Delphine Farlay; Thierry Douillard; Sylvain Meille; Helene Follet; Roland Chapurlat; Jérôme Chevalier; Georges Boivin
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

6.  Correlation between the compressive strength of iliac and vertebral trabecular bone in normal individuals.

Authors:  L Mosekilde; A Viidik; L Mosekilde
Journal:  Bone       Date:  1985       Impact factor: 4.398

7.  The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.

Authors:  Nicole C Wright; Anne C Looker; Kenneth G Saag; Jeffrey R Curtis; Elizabeth S Delzell; Susan Randall; Bess Dawson-Hughes
Journal:  J Bone Miner Res       Date:  2014-11       Impact factor: 6.741

8.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Authors:  A L Boskey; L Spevak; R S Weinstein
Journal:  Osteoporos Int       Date:  2008-09-04       Impact factor: 4.507

9.  Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Authors:  Samuel Gourion-Arsiquaud; Matthew R Allen; David B Burr; Deepak Vashishth; Simon Y Tang; Adele L Boskey
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

10.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

View more
  1 in total

Review 1.  Update on Menopausal Hormone Therapy for Fracture Prevention.

Authors:  Jan J Stepan; Hana Hruskova; Miloslav Kverka
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.